OTC Medicines

CHPA expresses its gratitude to New Jersey's governor, senator, and assembly members for shepherding the bill through the legislature. CHPA has long supported state efforts to curb teen OTC cough medicine abuse.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).

CHPA highlights the results of a recent five-state survey from the Asthma and Allergy Foundation of America, which found that consumers on the whole, prefer full access to OTC medicine containing pseudoephedrine.

CHPA applauds the Energy and Commerce Committee on House passage of the 21st Century Cures initiative. CHPA looks forward to the implementation of these provisions and believes it will help accelerate the discovery, development, and delivery of new treatments and cures for patients

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).